Cyclacel Pharmaceuticals, Inc.
General ticker "CYCC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $242.4M (TTM average)
Cyclacel Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -20.1%.
Estimated limits based on current volatility of 8.4%: low 4.51$, high 5.34$
Factors to consider:
- Company pays dividends (irregularly): last record date 2025-04-29, amount 0.15$ (Y2.91%)
- Total employees count: 200000 (0.0%) as of 2024
- Top business risk factors: Regulatory and compliance, Market competition, Supply chain disruptions, Operational and conduct risks, Litigation risks
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [18.33$, 86.23$]
- 2025-12-31 to 2026-12-31 estimated range: [8.05$, 36.75$]
Short-term CYCC quotes
Long-term CYCC plot with estimates
Financial data
| YTD | 2024-12-31 |
|---|---|
| Operating Revenue | $0.04MM |
| Operating Expenses | $12.05MM |
| Operating Income | $-12.00MM |
| Non-Operating Income | $0.01MM |
| R&D Expense | $6.66MM |
| Income(Loss) | $-11.99MM |
| Taxes | $-0.78MM |
| Profit(Loss)* | $-11.21MM |
| Stockholders Equity | $-2.17MM |
| Assets | $4.09MM |
| Operating Cash Flow | $-7.99MM |
| Financing Cash Flow | $7.82MM |
| Earnings Per Share** | $-1.35 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.